• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤维蛋白特异性且有效的血栓溶解需要纤溶酶原激活剂,并且它们要按顺序而非同时组合。

Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

作者信息

Pannell R, Li S, Gurewich V

机构信息

Vascular Research Laboratory, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.

出版信息

J Thromb Thrombolysis. 2017 Aug;44(2):210-215. doi: 10.1007/s11239-017-1514-0.

DOI:10.1007/s11239-017-1514-0
PMID:28600623
Abstract

Thrombolysis with tissue plasminogen activator (tPA) has been a disappointment and has now been replaced by an endovascular procedure whenever possible. Nevertheless, thrombolysis remains the only means by which circulation in a thrombosed artery can be restored rapidly. In contrast to tPA monotherapy, endogenous fibrinolysis uses both tPA and urokinase plasminogen activator (uPA), whose native form is a proenzyme, prouPA. This combination is remarkably effective as evidenced by the fibrin degradation product, D-dimer, which is invariably present in plasma. The two activators have complementary mechanisms of plasminogen activation and are synergistic in combination. Since tPA initiates fibrinolysis when released from the vessel wall and prouPA is in the blood, they induce fibrinolysis sequentially. It was postulated that this may be more effective and fibrin-specific. The hypothesis was tested in a model of clot lysis in plasma in which a clot was first exposed to tPA for 5 min, washed and incubated with prouPA. Lysis was compared with that of clots incubated with both activators simultaneously. The sequential combination was almost twice as effective and caused less fibrinogenolysis than the simultaneous combination (p < 0.0001) despite having significantly less tPA, as a result of the wash. A mechanism is described by which this phenomenon can be explained. The findings are believed to have significant therapeutic implications.

摘要

使用组织型纤溶酶原激活剂(tPA)进行溶栓治疗效果不佳,现在只要有可能就已被血管内介入治疗所取代。然而,溶栓仍然是迅速恢复血栓形成动脉血液循环的唯一方法。与tPA单一疗法不同,内源性纤溶作用同时使用tPA和尿激酶型纤溶酶原激活剂(uPA),其天然形式是一种酶原,即单链尿激酶型纤溶酶原激活剂(pro-uPA)。纤维蛋白降解产物D-二聚体始终存在于血浆中,这证明这种组合非常有效。这两种激活剂具有互补的纤溶酶原激活机制,且联合使用具有协同作用。由于tPA从血管壁释放时启动纤溶作用,而pro-uPA存在于血液中,它们依次诱导纤溶作用。据推测,这种方式可能更有效且对纤维蛋白具有特异性。该假设在血浆凝块溶解模型中进行了测试,在该模型中,凝块首先暴露于tPA 5分钟,冲洗后再与pro-uPA一起孵育。将其溶解情况与同时用两种激活剂孵育的凝块进行比较。尽管冲洗后tPA含量显著减少,但序贯组合的效果几乎是同时组合的两倍,且纤维蛋白原溶解较少(p < 0.0001)。本文描述了一种可以解释这种现象的机制。这些发现被认为具有重要的治疗意义。

相似文献

1
Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.纤维蛋白特异性且有效的血栓溶解需要纤溶酶原激活剂,并且它们要按顺序而非同时组合。
J Thromb Thrombolysis. 2017 Aug;44(2):210-215. doi: 10.1007/s11239-017-1514-0.
2
Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.重组人C1抑制剂在最佳纤维蛋白溶解过程中可防止突变型尿激酶原引起的非特异性蛋白水解。
Thromb Haemost. 2009 Aug;102(2):279-86. doi: 10.1160/TH08-09-0598.
3
Clot penetration and retention by plasminogen activators promote fibrinolysis.纤溶酶原激活物促进血栓穿透和滞留,从而促进纤维蛋白溶解。
Biochem Pharmacol. 2013 Jan 15;85(2):216-22. doi: 10.1016/j.bcp.2012.10.011. Epub 2012 Oct 23.
4
Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.组织型纤溶酶原激活剂和尿激酶原的互补作用模式,据此可解释它们对血栓溶解的协同效应。
J Clin Invest. 1988 Mar;81(3):853-9. doi: 10.1172/JCI113394.
5
A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.组织型纤溶酶原激活剂与尿激酶原的疗效及特异性比较研究:协同作用及不同非选择性阈值的证明
Thromb Res. 1986 Oct 15;44(2):217-28. doi: 10.1016/0049-3848(86)90137-4.
6
Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.协同纤维蛋白溶解作用:组织型纤溶酶原激活剂与重组葡萄球菌激酶在体外的联合效应
Biochim Biophys Acta. 2016 Apr;1860(4):629-35. doi: 10.1016/j.bbagen.2015.12.022. Epub 2015 Dec 23.
7
Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.吸血蝙蝠唾液纤溶酶原激活剂可在血浆环境中促进血浆凝块的强力溶解,而不会引起液相纤溶酶原激活。
Thromb Haemost. 1992 Aug 3;68(2):165-9.
8
Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.纤溶酶原激活剂的纤维蛋白特异性影响纤维蛋白溶解效率及对超声的反应性:九种纤溶酶原激活剂的体外比较
Thromb Haemost. 1999 Apr;81(4):605-12.
9
Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.可溶性纤维蛋白降解产物增强组织型纤溶酶原激活物诱导的纤维蛋白原蛋白水解作用。
J Clin Invest. 1991 Mar;87(3):1082-90. doi: 10.1172/JCI115069.
10
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶在体外血浆环境中对血凝块溶解不存在协同作用。
Thromb Haemost. 1986 Aug 20;56(1):35-9.

引用本文的文献

1
Optimization and characterization of collagenase KU665299 and its application in effective in-vitro clot digestion.胶原酶KU665299的优化、表征及其在体外有效凝块消化中的应用
Biotechnol Lett. 2025 Jul 22;47(4):79. doi: 10.1007/s10529-025-03615-2.
2
Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States.纤溶抑制和低纤溶不是同义词:区分低纤溶状态的临床意义。
Semin Thromb Hemost. 2023 Jul;49(5):433-443. doi: 10.1055/s-0042-1758057. Epub 2022 Nov 1.
3
An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.

本文引用的文献

1
Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved.治疗性溶栓:如何提高疗效和安全性。
J Am Coll Cardiol. 2016 Nov 8;68(19):2099-2106. doi: 10.1016/j.jacc.2016.07.780.
2
Discovery and characterization of an antibody directed against exosite I of thrombin.发现并鉴定一种靶向凝血酶外切位点 I 的抗体。
J Thromb Haemost. 2016 Jan;14(1):137-42. doi: 10.1111/jth.13171. Epub 2015 Dec 29.
3
Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.小剂量组织型纤溶酶原激活剂(tPA)与低剂量突变型尿激酶原(proUK)序贯协同组合实现高效纤维蛋白溶解。
用于评估远程磁性纳米颗粒运动和纤维蛋白溶解的体外模型系统。
Int J Nanomedicine. 2020 Mar 9;15:1549-1568. doi: 10.2147/IJN.S237395. eCollection 2020.
4
Structural Biology and Protein Engineering of Thrombolytics.溶栓剂的结构生物学与蛋白质工程
Comput Struct Biotechnol J. 2019 Jul 2;17:917-938. doi: 10.1016/j.csbj.2019.06.023. eCollection 2019.
PLoS One. 2015 Mar 26;10(3):e0122018. doi: 10.1371/journal.pone.0122018. eCollection 2015.
4
Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.尿激酶型纤溶酶原激活剂基因敲除小鼠中血栓溶解失败:正常骨髓来源细胞的挽救作用。
Circulation. 2003 Feb 18;107(6):869-75. doi: 10.1161/01.cir.0000050149.22928.39.
5
Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.能诱导高效血栓溶解且不干扰止血的尿激酶原突变体。
Circ Res. 2002 Apr 19;90(7):757-63. doi: 10.1161/01.res.0000014825.71092.bd.
6
Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).相互的尿激酶原/纤溶酶原激活动力学——由与聚(D-赖氨酸)结合的尿激酶受体形成的模板所刺激
Eur J Biochem. 1997 Apr 15;245(2):316-23. doi: 10.1111/j.1432-1033.1997.00316.x.
7
A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.一种对尿激酶原进行的定点诱变,可大幅降低其内在活性。
Biochemistry. 1996 Nov 12;35(45):14070-6. doi: 10.1021/bi9605393.
8
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.尿激酶型纤溶酶原激活剂在缺乏其受体或组织型纤溶酶原激活剂的情况下对纤维蛋白清除有效。
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5899-904. doi: 10.1073/pnas.93.12.5899.
9
Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.血浆凝块溶解过程中纤维蛋白网络的重排及纤溶成分的空间分布。共聚焦显微镜研究。
J Biol Chem. 1996 Jan 26;271(4):2133-8. doi: 10.1074/jbc.271.4.2133.
10
The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.组织型纤溶酶原激活剂、链激酶或两者联用对急性心肌梗死后冠状动脉通畅、心室功能及生存率的影响。
N Engl J Med. 1993 Nov 25;329(22):1615-22. doi: 10.1056/NEJM199311253292204.